**Supplemental Table 3. Odds ratio and 95% confidence interval for comparing patient-reported outcomes (FACIT-F response[a], HAQ-DI response[b]) at week 24 between each guselkumab group and placebo within patient subgroups defined by baseline demographics, disease characteristics, and DMARD use at baseline among pooled DISCOVER-1 and DISCOVER-2 patients. Prior to Week 24, patients meeting treatment failure criteria were considered non-responders. Missing data through Weeks 24 and 52 were imputed as non-response.**

| | FACIT-F Response[a] | | HAQ-DI Response[b] | |
|---|---|---|---|---|
| | Odds Ratio (95% CI) | | | |
| | GUS 100 mg Q4W | GUS 100 mg Q8W | GUS 100 mg Q4W | GUS 100 mg Q8W |
| **All patients** | 2.2 (1.6, 2.9) | 1.9 (1.4, 2.6) | 2.9 (2.1, 4.0) | 2.3 (1.7, 3.1) |
| **Sex** | | | | |
| Male | 2.4 (1.6, 3.7) | 1.7 (1.2, 2.6) | 3.3 (2.1, 5.2) | 1.9 (1.2, 2.9) |
| Female | 1.8 (1.2, 2.8) | 2.2 (1.4, 3.3) | 2.5 (1.6, 3.9) | 2.8 (1.8, 4.3) |
| **BMI (kg/m²)** | | | | |
| <25 | 2.1 (1.1, 3.7) | 2.3 (1.3, 4.1) | 3.0 (1.6, 5.7) | 1.9 (1.0, 3.4) |
| 25 to <30 | 2.0 (1.2, 3.3) | 1.7 (1.0, 2.7) | 2.7 (1.6, 4.5) | 2.2 (1.3, 3.7) |
| ≥30 | 2.4 (1.5, 3.7) | 2.0 (1.2, 3.1) | 3.2 (2.0, 5.4) | 2.7 (1.6, 4.6) |
| **Swollen joint count** | | | | |
| <10 | 2.6 (1.7, 3.9) | 2.1 (1.4, 3.1) | 3.4 (2.2, 5.3) | 2.3 (1.5, 3.6) |
| 10-15 | 1.7 (1.0, 2.9) | 1.4 (0.8, 2.5) | 3.0 (1.7, 5.5) | 2.6 (1.4, 4.7) |
| >15 | 1.9 (1.0, 3.6) | 2.4 (1.3, 4.7) | 2.1 (1.1, 4.0) | 2.0 (1.0, 3.8) |
| **Tender joint count** | | | | |
| <10 | 1.6 (0.8, 3.3) | 1.4 (0.7, 2.8) | 3.1 (1.3, 7.5) | 3.6 (1.5, 8.9) |
| 10-15 | 2.3 (1.3, 3.9) | 1.8 (1.1, 3.1) | 3.9 (2.1, 7.1) | 2.5 (1.4, 4.4) |
| >15 | 2.3 (1.5, 3.4) | 2.2 (1.5, 3.3) | 2.6 (1.7, 3.9) | 2.0 (1.3, 3.0) |
| **PsA duration (years)** | | | | |
| <1 | 2.0 (0.9, 4.2) | 2.8 (1.3, 5.7) | 3.0 (1.3, 7.0) | 6.1 (2.6, 14.4) |
| ≥1 to <3 | 2.2 (1.2, 4.1) | 1.5 (0.8, 2.7) | 4.9 (2.6, 9.6) | 3.3 (1.7, 6.3) |
| ≥3 | 2.2 (1.5, 3.2) | 1.9 (1.3, 2.8) | 2.4 (1.6, 3.6) | 1.5 (1.0, 2.3) |
| **CRP (mg/dL)** | | | | |
| <1 | 1.9 (1.3, 2.9) | 1.9 (1.3, 2.8) | 3.4 (2.2, 5.3) | 2.3 (1.5, 3.6) |
| 1 to <2 | 3.0 (1.5, 5.9) | 2.1 (1.1, 4.2) | 4.2 (2.0, 8.6) | 2.5 (1.2, 5.1) |
| ≥2 | 2.3 (1.3, 4.1) | 1.9 (1.1, 3.2) | 1.9 (1.0, 3.3) | 2.2 (1.3, 3.8) |
| **csDMARD/MTX use** | | | | |
| None | 3.4 (2.0, 5.8) | 3.0 (1.8, 5.1) | 7.3 (3.8, 14.1) | 5.1 (2.6, 9.7) |
| Any csDMARD | 1.8 (1.2, 2.5) | 1.6 (1.1, 2.2) | 2.1 (1.5, 3.1) | 1.8 (1.2, 2.6) |
| MTX | 1.8 (1.2, 2.6) | 1.5 (1.0, 2.2) | 2.2 (1.5, 3.2) | 1.4 (1.0, 2.2) |

[a]≥ 4-point improvement in FACIT-F score from baseline. The FACIT-F score is calculated based on the FACIT-fatigue questionnaire that comprises of 13 questions, with each question graded on a 5-point scale (0-4). The FACIT-F scores can range from 0 to 52 with higher scores indicating less fatigue.

[b]≥0.35-point improvement in HAQ-DI score from baseline among patients with a HAQ-DI score ≥0.35 at baseline. The score is the average of the computed categories scores (dressing, arising, eating, walking, hygiene, gripping and daily living). Lower scores are indicative of better functioning.

*BMI=Body mass index, CI=confidence interval, CRP=C-reactive protein, csDMARD=Conventional synthetic disease-modifying antirheumatic drug, FACIT-F= Functional Assessment of Chronic Illness Therapy-Fatigue, GUS=Guselkumab, HAQ-DI= Health Assessment Questionnaire-Disability Index, MTX=Methotrexate, PsA=Psoriatic arthritis, Q4W/Q8W=every four weeks/every eight weeks*